Norman Schwartz compensation by year
BIO-RAD LABORATORIES Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $914,320 | $922,022 | $942,468 | $950,000 | $986,538 | $987,885 | $1,030,154 | $1,040,000 | $1,059,500 | $1,089,877 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| Stock awards | $2,389,800 | $2,807,740 | $4,239,950 | $3,865,744 | $3,785,446 | $4,126,907 | $5,398,348 | $6,211,537 | $4,557,805 | $4,856,574 |
| Option awards | $829,917 | $1,012,928 | $1,711,111 | $1,277,192 | $1,193,773 | $1,423,476 | $0 | $0 | $2,280,086 | $1,458,975 |
| Non-equity incentive | $720,273 | $637,818 | $490,200 | $1,143,383 | $2,000,094 | $2,132,330 | $1,073,406 | $0 | $364,003 | $562,088 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| All other | $22,013 | $24,168 | $255,685 | $24,734 | $26,572 | $25,327 | $26,077 | $212,341 | $28,077 | $28,327 |
| Total | $4,876,323 | $5,404,676 | $7,639,414 | $7,261,053 | $7,992,423 | $8,695,925 | $7,527,985 | $7,463,878 | $8,289,471 | $7,995,841 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-RAD LABORATORIES, INC. DEF 14A filed March 25, 2026, accession 0000012208-26-000020, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIO-RAD LABORATORIES, INC. filed document, accession 0000012208-26-000020. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 16,439 | $4,980,853 | — |
| RSU | 10,367 | $3,141,097 | — |
| RSU | 6,010 | $1,820,970 | — |
| RSU | 2,082 | $630,825 | — |
| Option | 11,671 | — | $256.45 |
| Option | 10,603 | — | $343.76 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-RAD LABORATORIES, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2025 proxy (filed March 25, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-06 | Tax withholding | — | 1,854 | $386.11 | 449,019 |
| 2026-09-06 | Exercise or conversion | — | 3,455 | $0.00 | 450,873 |
| 2026-09-06 | Exercise or conversion derivative | — | 3,455 | $0.00 | 6,912 |
| 2026-09-05 | Tax withholding | — | 2,876 | $386.11 | 447,418 |
| 2026-09-05 | Exercise or conversion derivative | — | 4,109 | $0.00 | 12,330 |
| 2026-09-05 | Exercise or conversion | — | 4,109 | $0.00 | 450,294 |
| 2026-09-04 | Grant or award derivative | — | 17,251 | $0.00 | 17,251 |
| 2026-09-01 | Exercise or conversion derivative | — | 2,082 | $0.00 | 0 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments BIO-RAD LABORATORIES discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control, no termination | — | $11,116,913 | — | $11,116,913 |
| Involuntary termination without cause | $1,098,000 | — | — | $1,098,000 |
| Change in control and involuntary termination | $1,362,638 | $11,116,913 | $0 | $12,479,551 |
Per the Potential Payments Upon Termination or Change in Control table in BIO-RAD LABORATORIES, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
BIO-RAD LABORATORIES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Norman Schwartz · this page | Chief Executive Officer and Chairman | $7,995,841 |
| Jonathan DiVincenzo | President and Chief Operating Officer | $3,680,772 |
| Roop Lakkaraju | Executive Vice President, Chief Financial Officer | $2,990,738 |
| Rajat Mehta | Executive Vice President, Global Commercial Operations | $2,680,042 |
| James Barry | Executive Vice President and President, Life Science Group | $2,611,227 |
Board service
BIO-RAD LABORATORIES board · FY2021–FY2025How this board is paid
Company policy: BIO-RAD LABORATORIES pays directors a $200,000 cash retainer and $100,000 in RSUs. As stated in BIO-RAD LABORATORIES's FY2025 proxy.
The full BIO-RAD LABORATORIES compensation record
free company briefThis page is one person within BIO-RAD LABORATORIES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIO-RAD LABORATORIES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIO-RAD LABORATORIES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-RAD LABORATORIES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BIO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.